DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) — DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes. Today the Company announces that management will be meeting with investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference held virtually on February 13-14, 2024.
Interested qualified investors must register for the conference through Oppenheimer’s customer portal, and may arrange meetings either through the conference portal or directly with the Company via email at [email protected]. Investors are requested to preregister for the event.
About the 34th Annual Oppenheimer Healthcare Life Sciences Conference
This conference will provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry: bio & specialty pharmaceuticals; biotechnology; medical devices; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers. The Healthcare ecosystem has never been as complex nor as full of opportunities. Therapies and treatments are evolving more rapidly than investors have been able to keep up with. The 34th Annual Oppenheimer Healthcare Life Sciences Conference will showcase nearly 300 companies that will likely shape the industry for the next decade to come.
About DepYmed, Inc.
DepYmed Inc., is a New York based rare disease and cancer therapeutic development company that was founded to capitalize on the scientific discoveries of the Tonks lab at Cold Spring Harbor Laboratory in the physiological function of PTP1B and ways to modulate its role in various human diseases. DepYmed is currently developing a new class of potent, orally bioavailable small molecule inhibitors of the enzyme PTP1B as novel therapeutics for Rett Syndrome and different types of cancer. In addition, DepYmed has also discovered a novel class of small molecules with copper chelating properties that it is developing as potential therapeutic agents for such diseases as Wilson disease and various cancers. The company is actively developing a deep pipeline of novel compounds with broad therapeutic potential in these emerging drug classes in collaboration with Cold Spring Harbor Laboratory. For more information, please visit the Company’s website at: www.depymed.com.
For Media Inquiries please contact:
Jules Abraham
JQA Partners, Inc.
[email protected]
917-885-7378
DepYmed:
[email protected]
